newsfilter
← Latest News
GlobeNewswire·

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

RHHBY
  • Roche Group sales grew +6% at constant exchange rates (CER) and +1% in Swiss francs (CHF) in the first nine months of 2026, driven by high demand for innovative medicines & diagnostics.
  • Third-quarter sales increased +7% at CER & +8% in CHF, as exchange rates stabilized compared to earlier periods.
  • Pharmaceuticals Division sales rose +7% at CER & +2% in CHF, led by top growth drivers Xolair, Hemlibra, Ocrevus, Phesgo, & Vabysmo.
  • Diagnostics Division sales grew +4% at CER & were stable in CHF, with demand for core lab & pathology solutions offsetting healthcare pricing reforms in China.
  • US FDA approved Tecentriq for adjuvant treatment of stage-III DNA mismatch repair colon cancer & Enspryng for thyroid eye disease.
  • US FDA granted Priority Review for fenebrutinib in relapsing & primary progressive multiple sclerosis, Enspryng in MOGAD, & cleared Elecsys pTau217 as the first single-biomarker blood test for Alzheimer's disease.
  • EU approved Susvimo for neovascular age-related macular degeneration (nAMD) & Ocrevus for paediatric relapsing multiple sclerosis.
  • Positive Phase III data reported for sefaxersen in IgA nephropathy, Lunsumio in follicular lymphoma, & Tam-Peli in relapsed small-cell lung cancer.
  • Phase II results showed enicepatide achieved significant weight loss & HbA1c reduction in type 2 diabetes & obesity.
  • US clearance granted for Elecsys pTau217 to aid in identifying amyloid pathology associated with Alzheimer's disease.
  • Launched real-time PCR tests for Cyclospora cayetanensis outbreak response & delivered molecular tests for Ebola response in the Democratic Republic of the Congo.
  • Expanded manufacturing & R&D capacity with new facilities in Hillsboro (injectable medicines), Boston (Innovation Center for cardiovascular, renal, & metabolic diseases), & Basel (small molecules).
  • Proposed Dr. Christophe Weber as a nominee for the Board of Directors at the 2027 Annual General Meeting.
  • Confirmed full-year 2026 outlook expecting Group sales growth in the mid single-digit range (CER) & core earnings per share growth in the high single-digit range (CER).
  • Sales in Japan surged +25% at CER & +10% in CHF, while US sales grew +5% at CER & were stable in CHF.
  • Diagnostics sales in Asia-Pacific declined -4% at CER due to pricing reforms in China, while Latin America grew +12% at CER.
  • Sales of products with expired patents decreased by CHF 0.4 billion at CER, while top five growth drivers achieved total sales of CHF 16.8 billion.